Most MedTech startups don’t fail because the science stops working. They fail because they can’t hire fast enough after the money arrives.
That’s not a headline. That’s a pattern I’ve watched play out more times than I’d like to count.
The post-funding illusion
Founders often assume that a Series A or B announcement changes their position in the talent market. In consumer tech, it does. Engineers move toward momentum. Capital signals safety.
In MedTech, experienced candidates read a funding round differently. They’re not asking how much you raised. They’re asking what device class you’re in, what your regulatory pathway looks like, whether you’ve started your technical file, and what your realistic timeline to first submission is. They’re performing due diligence on you — because they’ve seen well-funded startups collapse under regulatory pressure before, and they have no interest in being part of that story.
This is the first thing most founders get wrong. The announcement doesn’t do the work for you.
The talent pool is smaller than your model assumes
Let’s be specific about what post-funding MedTech hiring actually requires.
A Quality Director who has built a QMS from the ground up under ISO 13485 — not just maintained one. A Head of Regulatory Affairs who can navigate FDA 510(k) or PMA pathways and EU MDR simultaneously, and understands how those frameworks interact with your intended use. A Clinical Operations lead who has managed studies to ICH-GCP standards and understands site governance, data integrity obligations, and the realities of working within NHS or hospital-system constraints.
These are not interchangeable profiles. They are not abundant. And they are almost never actively looking.
The subset of candidates who have done this work, at the right device class, in a startup environment rather than a large OEM, is genuinely small. When you’re competing for them against better-known names with longer runways, the quality of your process — your brief, your timeline, your ability to present a credible regulatory narrative — determines whether you even get a conversation.
The window is shorter than you think
Post-funding momentum has a half-life. There’s a narrow period — typically eight to twelve weeks after close — where your story is fresh, candidates are curious, and the conditions for a strong hire are most favourable. Founders who wait until the ink is dry to think about recruitment consistently lose that window.
The ones who hire well engage their recruitment partners before the announcement. They arrive at market with a defined brief, a clear regulatory context, and a process designed to move at pace without cutting corners on assessment.
The bottleneck is almost never the market
There is enough specialist talent in MedTech to meet most post-funding hiring needs. What’s scarce isn’t the people, it’s hiring processes built for this environment. Generic job briefs, slow internal approvals, and interview panels that can’t speak credibly to regulatory experience will lose you the candidates you most need to attract.
The market will respond to the right approach. The question is whether your process deserves it.
